ATRX and cancer: This suggests that inhibition of F2 (for example RAD54/RAD54B) would be particularly effective to sensitize cancer cells overexpressing F1 components (e.g. RAD51 paralogs, RAD51, RAD52, BRAC2 [41]–[45]), a non-intuitive insight derived from the mathematical modeling.